Working within a community experiencing a high number of confirmed COVID-19 cases is requiring a strategic approach to manage patient care…
Mobilizing a Long-Term Telemedicine Solution: Q&A with Karen Ferguson
Looking beyond the COVID-19 pandemic, one practice has combined its telemedicine functionality with long-term workflow solutions, including telemedicine technology that integrates with its electronic health records system…
Transitioning to a Virtual Practice: Q&A with Lisa Criscione-Schreiber, MD, MEd
A quick shift to virtual teaching and patient care is just one of many changes rheumatologists at Duke University are adapting to during the COVID-19 pandemic…
Join the ACR COVID-19 Clinical Guidance Town Hall: May 6
In response to the recently published clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic, the ACR is hosting a virtual town hall for the rheumatology community on Wednesday, May 6, at 7–8 p.m. EDT, to review the recommendations. Moderated by ACR President Ellen M. Gravallese, MD, and ACR…
Fear & Hope in the Era of the Modern Plague
This plague has affected each one of us, our families and friends, and abruptly, it has altered the way we relate to one another.
3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome
CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…
Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule
(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…
Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
(Reuters)—On April 27, Regeneron Pharmaceuticals Inc. and Sanofi SA said on Monday that their arthritis drug sarilumab (Kevzara) may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease. The drugmakers said they would test high doses of sarilumab only in critically…
U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…
Locum Tenens as a Resource for Practices During the COVID-19 Outbreak
As the number of COVID-19 cases continues to rise in the U.S., the fast spread of the virus is causing gaps in practice staffing, and patient influx will likely increase, leaving systems needing more providers. The use of locum tenens physicians can help practice fill gaps at your organization caused by COVID-19. Below we offer…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 27
- Next Page »